Positive Patient Stories™

Transcept Pharmaceuticals Archived News

Keyword Search
 
2017 | 2014 | 2013
DateTitle 
12/19/13Transcept Final Voting Results for Special Meeting of Stockholders Provide Strong Support for Current Board of Directors and Tax Benefit Preservation Program
12/17/13Transcept Pharmaceuticals Statement on the Withdrawal of the Unsolicited Indication of Interest from Retrophin, Inc.
12/16/13Transcept Pharmaceuticals Announces That Largest Stockholder, Roumell Asset Management, Declares Support Of Company Strategies
12/13/13Transcept Pharmaceuticals Announces that Glass Lewis & Co. Recommends "AGAINST" All Proposals Subject to a Vote at the December 19, 2013 Special Meeting of Stockholders
12/11/13Transcept Pharmaceuticals Announces that ISS Proxy Advisory Services Recommends "AGAINST" All Proposals Subject to a Vote at the December 19, 2013 Special Meeting of Stockholders
12/04/13Transcept Pharmaceuticals Provides Update to Key Initiatives Being Undertaken to Increase Stockholder Value
11/13/13Transcept Pharmaceuticals Announces Plans to Reduce Expenses Through a Reduction in Force and a Restructuring of its Board of Directors
11/07/13Transcept Pharmaceuticals Reports Third Quarter Financial Results
11/04/13Transcept Pharmaceuticals to Report Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013
10/07/13Transcept Sets Special Stockholders Meeting
09/30/13Transcept Pharmaceuticals Statement on Request by Retrophin, Inc. to Acquire Up To 15 Percent of the Outstanding Common Stock of Transcept
09/25/13Transcept Pharmaceuticals Statement on Unsolicited Acquisition Proposal from Retrophin, Inc.
09/25/13Transcept And Shin Nippon Biomedical Laboratories Announce Global Licensing Agreement For Advanced Acute Migraine Treatment
09/13/13Transcept Pharmaceuticals, Inc. Adopts Tax Benefit Preservation Plan
08/07/13Transcept Pharmaceuticals Reports Second Quarter Financial Results
07/29/13Transcept Pharmaceuticals to Report Second Quarter 2013 Financial Results and Host Conference Call on August 7, 2013
05/08/13Transcept Pharmaceuticals Reports First Quarter 2013 Financial Results
05/01/13Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013
04/10/13Thomas J. Dietz, Ph.D., Appointed To The Transcept Pharmaceuticals Board Of Directors
02/28/13Transcept Pharmaceuticals to Present at Cowen and Company Health Care Conference on March 6
02/27/13Transcept Pharmaceuticals Reports Fourth Quarter And Full Year 2012 Financial Results
02/21/13Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Financial Results and Host Conference Call on February 27, 2013
02/05/13Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
01/10/13Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements for Zolpidem Based Prescription Sleep Aids Administered at Bedtime

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.